Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

87.11
-0.3600-0.41%
Post-market: 87.02-0.0900-0.10%19:30 EDT
Volume:1.09M
Turnover:94.72M
Market Cap:12.27B
PE:-38.14
High:88.46
Open:87.90
Low:85.94
Close:87.47
52wk High:95.49
52wk Low:20.45
Shares:140.86M
Float Shares:122.00M
Volume Ratio:1.09
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:26.36
PE(LYR):-7,144.26

Loading ...

Arrowhead says EU grants marketing authorization for REDEMPLO in adult FCS patients

Reuters
·
Jun 23

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for Redemplo® (Plozasiran) to Reduce Triglycerides in Adults With Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS
·
Jun 23

Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update

Simply Wall St.
·
Jun 20

Arrowhead Pharmaceuticals to host cardiometabolic R&D webinar in 2026 Summer Series

Reuters
·
Jun 18

Arrowhead Pharma director Matthew Gregory Cohen files initial beneficial ownership statement

Reuters
·
Jun 18

Movement Alert|Arrowhead Research Corporation Rises 5.06% in Regular Trading, Alzheimer Disease siRNA Drug Clinical Progress Continues to Drive Momentum

Market Focus
·
Jun 18

Arrowhead Pharmaceuticals Is Maintained at Market Perform by Leerink Partners

Dow Jones
·
Jun 17

Arrowhead Pharmaceuticals : Leerink Partners Raises Target Price to $72 From $61

THOMSON REUTERS
·
Jun 17

U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower

Reuters
·
Jun 17

Arrowhead Pharmaceuticals Adds Experienced Healthcare Investor to Board

TIPRANKS
·
Jun 17

Arrowhead Pharmaceuticals appoints Vida Ventures’ Matt Cohen to board

Reuters
·
Jun 17

Movement Alert|Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed

Market Focus
·
Jun 12

Arrowhead Pharmaceuticals (ARWR) Valuation Check After New Plozasiran And ARO-INHBE Clinical Updates

Simply Wall St.
·
Jun 06

Analysts’ Top Healthcare Picks: Arrowhead Pharmaceuticals (ARWR), Veeva Systems (VEEV)

TIPRANKS
·
Jun 04

Arrowhead Pharmaceuticals joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
Jun 02

Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results

Simply Wall St.
·
May 29

Arrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained

TIPRANKS
·
May 28

Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE

TIPRANKS
·
May 27

Arrowhead posts Phase 1/2a data showing ARO-INHBE cuts liver fat 44% in obese adults

Reuters
·
May 27

Arrowhead presents clinical cardiometabolic data at EAS Congress

TIPRANKS
·
May 27